Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 10/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | IDH1 | O75874 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | RUVBL1 | Q9Y265 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19481975 | 1.00 | RET (0.39) | RETHRH3IDH1TDP1RUVBL1 | |
| SCHEMBL19481807 | 0.93 | HRH3 (0.43) | HRH3TDP1RUVBL1MMP2MMP13 | |
| SCHEMBL19486807 | 0.93 | RET (0.38) | RETHRH3RUVBL1MMP2MMP13 | |
| SCHEMBL19481952 | 0.93 | RET (0.38) | RETHRH3RUVBL1MMP2MMP13 | |
| SCHEMBL19486484 | 0.92 | RET (0.39) | RETIDH1RUVBL1TBK1ALDH1A1 | |
| SCHEMBL19481991 | 0.92 | RET (0.39) | RETIDH1RUVBL1TBK1ALDH1A1 | |
| SCHEMBL19486351 | 0.90 | HRH3 (0.41) | RETHRH3TDP1RUVBL1MMP2 | |
| SCHEMBL19486398 | 0.89 | MC4R (0.39) | RETALDH1A1 | |
| SCHEMBL19481945 | 0.89 | MC4R (0.39) | RETALDH1A1 | |
| SCHEMBL19486471 | 0.89 | MAPK8 (0.41) | RETIDH1TDP1RUVBL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3442977-B1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | BLUEPRINT MEDICINES CORP (US) | 2023-06-28 | — | — | EP | disclosed |
| US-20170298069-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | BLUEPRINT MEDICINES CORPORATION | 2017-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170298069-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | ACVR1, ACVR2A, ACVRL1 | RET 50/4885HRH3 2428/4885IDH1 1074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.